Novo NordiskSee all their emails

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class

A real announcement email from Novo Nordisk. Captured May 22, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class email from Novo Nordisk screenshot

Captured Announcement

Novo Nordisk announces a positive CHMP opinion for the Wegovy pill in the EU, highlighting weight-loss efficacy and cardiovascular benefits.

Corporate press release format. Logo at the top, followed by bulleted highlights, detailed body text, and a structured contact table. Minimalist, clean, and highly text-focused.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.